Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-13T00:47:59.026Z Has data issue: false hasContentIssue false
  • English
  • Français

Much to Do about Carbapenem-Resistant Enterobacteriaceae: Why Supplementing Surveillance May Be the Key to Stopping Spread

Published online by Cambridge University Press:  10 May 2016

Christopher D. Pfeiffer  and
Zintars G. Beldavs
Christopher D. Pfeiffer*
Affiliation:
Department of Hospital and Specialty Medicine, Portland Veterans Affairs Medical Center, Portland, Oregon; and Department of Medicine, Oregon Health and Science University, Portland, Oregon
Zintars G. Beldavs
Affiliation:
Public Health Division, Oregon Health Authority, Portland, Oregon
*
Portland Veterans Affairs Medical Center, PO Box 1034 P3-ID, Portland, OR 97239 (pfeiffec@ohsu.edu).
Get access Rights & Permissions [Opens in a new window]

Extract

(See the article by Thaden et al, on pages 978–983.)

It is critical to the future of public health to understand the burden of carbapenem-resistant Enterobacteriaceae (CRE) so that we can effectively target efforts to limit potential spread. The Centers for Disease Control and Prevention (CDC) classifies CRE as 1 of 3 “urgent” antibiotic resistance threats to public health because of the high mortality associated with CRE infection and its rapid dissemination in the United States.

What is the current burden of CRE disease? We can glean a snapshot of the national epidemiology of CRE from the CDC’s national surveillance. Rapid geographic spread is evident in the CDC’s national map of CRE, which indicates that all but 3 states now have identified CRE. Incidence by facility type, procedure, device, and organism all have considerable variation, providing preliminary indications where future prevention efforts might best be focused. The 2013 CRE Vital Signs states that 3.9% of short-stay acute care hospitals and 17.8% of long-term acute care hospitals have identified cases of CRE infection among those with catheter-associated urinary tract infection (CAUTI) or central line–associated bloodstream infection (CLABSI). The CDC also reported that 10% of Klebsiella species in intensive care unit (ICU) CLABSIs, ICU CAUTIs, and surgical site infections after colon surgery or coronary artery bypass grafting in 2011 were carbapenem resistant. Although CRE have been reported in most states, it is increasingly clear that wide regional variation exists, from regions of hyperendemicity, such as parts of New York City, to regions apparently free of CRE, such as Maine.

Type
Commentary
Information
Infection Control & Hospital Epidemiology , Volume 35 , Issue 8 , August 2014 , pp. 984 - 986
Copyright
© 2014 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed April 29, 2014.Google Scholar
2. Centers for Disease Control and Prevention. Tracking CRE. http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html. Accessed April 29, 2014.Google Scholar
3. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013;62(9):165–170.Google Scholar
4. Thaden, J, Lewis, S, Hazen, K, et al. Rising rates of carbapenem-resistant Enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol 2014;35(8):978–983 (in this issue).CrossRefGoogle Scholar
5. Epson, EE, Pisney, LM, Wendt, JM, et al. Carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase at an acute care hospital, Colorado, 2012. Infect Control Hosp Epidemiol 2014;35(4):390–397.CrossRefGoogle ScholarPubMed
6. Mathers, AJ, Hazen, KC, Carroll, J, et al. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the “menace” arrives in the new world. J Clin Microbiol 2013;51(2):680–683.Google Scholar
7. Nordmann, P, Poirel, L, Dortet, L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2012;18(9):1503–1507.Google Scholar
8. Vasoo, S, Cunningham, SA, Kohner, PC, et al. Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing gram-negative bacilli. J Clin Microbiol 2013;51(9):3097–3101.CrossRefGoogle ScholarPubMed
9. Tijet, N, Boyd, D, Patel, SN, Mulvey, MR, Melano, RG. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa . Antimicrob Agents Chemother 2013;57(9):4578–4580.Google Scholar
10. BioFire Diagnostics. FilmArray blood culture identification panel. http://filmarray.com/the-panels/. Accessed April 29, 2014.Google Scholar
11. Nanosphere. Verigene gram-negative blood culture test. http://www.nanosphere.us/products/gram-negative-blood-culture-test. Accessed April 29, 2014.Google Scholar
12. Pfeiffer, CD, Cunningham, MC, Poissant, T, et al. Establishment of a statewide network for carbapenem-resistant Enterobacteriaceae prevention in a low-incidence region. Infect Control Hosp Epidemiol 2014;35(4):356–361.CrossRefGoogle Scholar
13. Extensively drug resistant organism (XDRO) registry. https://www.xdro.org/. Accessed April 29, 2014.Google Scholar
14. Verhoef, J, Beaujean, D, Blok, H, et al. A Dutch approach to methicillin-resistant Staphylococcus aureus . Eur J Clin Microbiol Infect Dis 1999;18(7):461–466.Google Scholar
15. Ostrowsky, BE, Trick, WE, Sohn, AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001;344(19):1427–1433.Google Scholar
16. Schwaber, MJ, Carmeli, Y. An ongoing national intervention to contain the spread of carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2014;58(5):697–703.Google Scholar
17. Schwaber, MJ, Lev, B, Israeli, A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52(7):848–855.Google Scholar
18. Brennan, BM, Coyle, JR, Marchaim, D, et al. Statewide surveillance of carbapenem-resistant Enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol 2014;35(4):342–349.CrossRefGoogle ScholarPubMed
19. Won, SY, Munoz-Price, LS, Lolans, K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53(6):532–540.CrossRefGoogle ScholarPubMed
20. Lin, MY, Lyles-Banks, RD, Lolans, K, et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2013;57(9):1246–1252.Google Scholar